Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 9086 results
Found 9086 results.

Absorptiometry, Photon

Grant PM, Kitch D, McComsey GA, et al. "Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation." Clin. Infect. Dis.. 2013;57(10):1483-8.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
Hulgan T, Haubrich R, Riddler SA, et al. "European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142." AIDS. 2011;25(1):37-47.
Overton ETurner, Chan ES, Brown TT, et al. "Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial." Ann. Intern. Med.. 2015;162(12):815-24.
McComsey GA, Kendall MA, Tebas P, et al. "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV." AIDS. 2007;21(18):2473-82.
Hulgan T, Tebas P, Canter JA, et al. "Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy." J. Infect. Dis.. 2008;197(6):858-66.
Erlandson KM, Kitch D, Tierney C, et al. "Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density." AIDS. 2013;27(13):2069-79.
Mulligan K, Parker RA, Komarow L, et al. "Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial." J. Acquir. Immune Defic. Syndr.. 2006;41(5):590-7.
Dubé MP, Komarow L, Mulligan K, et al. "Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384." J. Acquir. Immune Defic. Syndr.. 2007;45(5):508-14.

Accidental Falls

Yin MT, Kendall MA, Wu X, et al. "Fractures after antiretroviral initiation." AIDS. 2012;26(17):2175-84.

Acquired Immunodeficiency Syndrome

L Wheat J, Connolly P, Smedema M, et al. "Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole." J. Antimicrob. Chemother.. 2006;57(6):1235-9.
Swindells S, Jiang H, A Mukherjee L, Winters M, Bosch RJ, Katzenstein D. "Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis." HIV Clin Trials. 2011;12(2):79-88.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. "Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES." PLoS ONE. 2013;8(6):e65306.
Williams P, Wu J, Cohn S, et al. "Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution." HIV Med.. 2009;10(5):290-301.
Verma A, Bradford Y, Verma SS, et al. "Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2017;27(3):101-111.
Yin MT, Kendall MA, Wu X, et al. "Fractures after antiretroviral initiation." AIDS. 2012;26(17):2175-84.
Kantor R, Bettendorf D, Bosch RJ, et al. "HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077." PLoS ONE. 2014;9(4):e93537.
Wohl DA, Kendall MA, Andersen J, et al. "Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030." HIV Clin Trials. 2009;10(3):143-52.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Bhasin S, Parker RA, Sattler F, et al. "Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity." J. Clin. Endocrinol. Metab.. 2007;92(3):1049-57.
Genberg BL, Wilson IB, Bangsberg DR, et al. "Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America." AIDS. 2012;26(11):1415-23.
Johnson DH, Venuto C, Ritchie MD, et al. "Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2014;24(4):195-203.
DiFrancesco R, Rosenkranz S, A Mukherjee L, et al. "Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial." Ther Drug Monit. 2010;32(4):458-66.
X Hu J, Lagakos SW. "Nonparametric estimation of the mean function of a stochastic process with missing observations." Lifetime Data Anal. 2007;13(1):51-73.
Grant PM, Komarow L, Sanchez A, et al. "Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164." HIV Clin Trials. 2014;15(4):133-9.
Robertson KR, Su Z, Margolis DM, et al. "Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort." Neurology. 2010;74(16):1260-6.

Pages